Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum subsp. infantis BLI-02
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum subsp. infantis BLI-02 is a probiotic bacterial strain developed by Glac Biotech Co., Ltd. Isolated from sources including healthy breast milk and the human gut, it is characterized as a live biotherapeutic or microbiome-based agent. Preclinical studies indicate that the strain is safe, lacking antibiotic resistance, mutagenicity, or toxicity. It demonstrates high survival rates in acidic and bile-rich environments and exhibits strong adherence to intestinal epithelial cells, suggesting potential for gut colonization. Additionally, BLI-02 has shown antimicrobial activity against pathogens such as *Vibrio parahaemolyticus*. It is primarily positioned as a research or commercial probiotic ingredient rather than a prescription pharmaceutical.
- Other names
- Bifidobacterium longum subsp. infantis BLI-02B. infantis BLI-02
Beyond the preview
Go deeper on Bifidobacterium longum subsp. infantis BLI-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum subsp. infantis BLI-02.